New Opportunities - Mechanisms of Early Vaccinia Viral Morphogensis

新机遇——早期牛痘病毒形态发生机制

基本信息

  • 批准号:
    7680587
  • 负责人:
  • 金额:
    $ 7.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-03-01 至 2009-02-28
  • 项目状态:
    已结题

项目摘要

Abstract Members of the poxvirus family have been investigated for their applications as vaccines and expression vectors, and more recently intently studied because of their use as potential biological weapons. Vaccinia virus, the prototypic member, evolves through multiple forms in acquiring infectivity, for which early membrane morphogenesis plays a key role. Even though viruses generally usurp host factors for its use, it remains unclear whether key host transport factors that are well known to act in membrane morphogenesis of cellular compartments participate in early vaccinia membrane morphogenesis. We have now discovered a role for coatomer, a host protein complex known to shape Coat Protein I (COP!) transport vesicles. However, insights into how coatomer participates in early viral morphogenesis reveals that the virus bypasses key regulatory mechanisms that form host COP1 vesicles, but instead its interaction with two proteins, the viral K7 and the host KDEL receptor (KDELR) through critical di-lysine residues is likely important. Thus, to gain further insight into how coatomer and its two interacting proteins contribute to viral replication, we propose two major aims. In one aim headed by Victor Hsu with proposed funding from NERCE, perturbation of coatomer will be examined for its effect in potentially accumulating particular viral forms. Moreover, the KDELR will be examined with respect to its distribution on viral forms and also whether its ligands have a role in viral replication. As another aim headed by Stuart lsaacs with proposed funding from MARCE, the viral K7 protein will be examine for effects upon its deletion and also when a mutant form that cannot interact with coatomer is expressed. This collaborative effort is responsive in multiple ways to the request for application under the "New Opportunities" initiative by the two respective Regional Centers of Excellence. First, we will be gaining insights into a Category A pathogen, for which we will not only elucidate novel mechanisms by which a host protein functions during viral replication, but also identify potential key target(s) for the future design of intervention against the most abundant infectious form of the virus. Second, funding of this proposal will allow one of the main investigators (Victor Hsu) to collaborate with a poxvirus expert (Stuart Isaacs), and thus, applying outside expertise in mechanisms of vesicular transport to critical issues in poxvirus biology. As viruses generally commandeer host mechanisms for their interaction with the host rather than inventing completely novel ones, the complementary expertise of the collaboration will likely enhance the elucidation of how vaccinia virus interacts with its host. Third, potential funding of this proposal will likely set the stage for an eventual more comprehensive application in the future, such as through the NIH R01 mechanism.
抽象的 Poxvirus家族的成员已被调查,因为他们的应用是疫苗和表达媒介,并且由于它们用作潜在的生物武器而被专心研究。原型成员Vaccinia病毒通过多种形式而发展,以获得感染性,对此,早期的膜形态发生起着关键作用。即使病毒通常占据宿主因素的使用,但仍不清楚众所周知,在细胞室的膜形态发生中众所周知的关键宿主转运因子是否参与了早期的疫苗膜形态发生。现在,我们发现了Coatomer的角色,Goatomer是一种宿主蛋白​​络合物,已知塑造涂层蛋白I(COP!)传输囊泡。然而,对外皮机如何参与早期病毒形态发生的见解表明,该病毒绕过形成宿主COP1囊泡的关键调节机制,而是与两个相互作用 蛋白质,病毒K7和宿主KDEL受体(KDELR)通过临界Di-Lysine残基很重要。因此,为了进一步了解涂层剂及其两种相互作用蛋白如何促进病毒复制,我们提出了两个主要目的。在一个由Victor hsu领导的一个目标中,Nerce的拟议资金将对面膜的扰动进行检查,以便对其在潜在地积累特定的病毒形式中的影响。此外,Kdelr将在病毒形式的分布以及是否是否 它的配体在病毒复制中起作用。作为由Stuart LSAACS领导的另​​一个目标,并向Marce提出了资金,病毒K7蛋白将检查其缺失的影响以及当表达无法与涂层物相互作用的突变体形式时。 这项协作努力以多种方式响应于两个各个地区卓越中心的“新机遇”倡议下的申请请求。首先,我们将获得对病原体类别的见解,为此,我们不仅会阐明宿主蛋白在病毒复制过程中起作用的新型机制,而且还确定了潜在的关键目标(S) 对最丰富的传染性形式的干预。其次,该提案的资金将允许一位主要的研究人员(Victor HSU)与Poxvirus Expert(Stuart Isaacs)合作,因此,将囊泡运输机制的外部专业知识应用于Poxvirus生物学的关键问题。作为病毒通常与主机互动而不是发明的指挥生主机机制 完全新颖的协作互补专业知识可能会增强疫苗病毒与宿主相互作用的方式的阐明。第三,该提案的潜在资金可能会为未来最终更全面的应用奠定基础,例如通过NIH R01机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stuart N. Isaacs其他文献

Antipyretic orders in a university hospital.
大学医院的退烧药单。
  • DOI:
    10.1016/0002-9343(90)90124-v
  • 发表时间:
    1990
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Stuart N. Isaacs;Peter Axelrod;Bennett Lorber
  • 通讯作者:
    Bennett Lorber
Poxvirus vaccines: the evolution of an 18th-century vaccine to the 21st century
  • DOI:
    10.1016/j.tips.2024.10.015
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Yuhong Xiao;Stuart N. Isaacs
  • 通讯作者:
    Stuart N. Isaacs

Stuart N. Isaacs的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stuart N. Isaacs', 18)}}的其他基金

XXIII International Poxvirus, Asfarvirus, and Iridovirus Conference
第二十三届国际痘病毒、阿斯法病毒和虹彩病毒会议
  • 批准号:
    9993673
  • 财政年份:
    2021
  • 资助金额:
    $ 7.09万
  • 项目类别:
Enhancement and Expansion: Penn Neurophysiology and Behavior Testing Facility
增强和扩展:宾夕法尼亚大学神经生理学和行为测试设施
  • 批准号:
    9120117
  • 财政年份:
    2016
  • 资助金额:
    $ 7.09万
  • 项目类别:
Novel approaches to propagate molluscum contagiosum virus in cell culture
在细胞培养中繁殖传染性软疣病毒的新方法
  • 批准号:
    9089855
  • 财政年份:
    2015
  • 资助金额:
    $ 7.09万
  • 项目类别:
Smallpox vaccine and vaccinia complement control protein
天花疫苗和牛痘补体控制蛋白
  • 批准号:
    7901695
  • 财政年份:
    2009
  • 资助金额:
    $ 7.09万
  • 项目类别:
Optimizing the formulation of a protein based smallpox vaccine
优化基于蛋白质的天花疫苗的配方
  • 批准号:
    7802243
  • 财政年份:
    2008
  • 资助金额:
    $ 7.09万
  • 项目类别:
Optimizing the formulation of a protein based smallpox vaccine
优化基于蛋白质的天花疫苗的配方
  • 批准号:
    7616506
  • 财政年份:
    2008
  • 资助金额:
    $ 7.09万
  • 项目类别:
Optimizing the formulation of a protein based smallpox vaccine
优化基于蛋白质的天花疫苗的配方
  • 批准号:
    8056790
  • 财政年份:
    2008
  • 资助金额:
    $ 7.09万
  • 项目类别:
Optimizing the formulation of a protein based smallpox vaccine
优化基于蛋白质的天花疫苗的配方
  • 批准号:
    8259455
  • 财政年份:
    2008
  • 资助金额:
    $ 7.09万
  • 项目类别:
Optimizing the formulation of a protein based smallpox vaccine
优化基于蛋白质的天花疫苗的配方
  • 批准号:
    7454535
  • 财政年份:
    2008
  • 资助金额:
    $ 7.09万
  • 项目类别:
Poxvirus
痘病毒
  • 批准号:
    7678786
  • 财政年份:
    2008
  • 资助金额:
    $ 7.09万
  • 项目类别:

相似国自然基金

mRNA反式调控基因转录的机制及其生物学功能
  • 批准号:
    32330018
  • 批准年份:
    2023
  • 资助金额:
    220 万元
  • 项目类别:
    重点项目
增材制造锌镁合金复合椎间融合器降解调控机制与生物学效应研究
  • 批准号:
    52301302
  • 批准年份:
    2023
  • 资助金额:
    20 万元
  • 项目类别:
    青年科学基金项目
基于脑-脊髓-视神经MRI影像特征的神经免疫疾病影像亚型及其分子生物学机制的多组学研究
  • 批准号:
    82330057
  • 批准年份:
    2023
  • 资助金额:
    220 万元
  • 项目类别:
    重点项目
秸秆还田下玉/豆间作系统的生物固氮效应及微生物学机制
  • 批准号:
    32301962
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
III-E型CRISPR-Cas系统的结构生物学及其应用研究
  • 批准号:
    32371276
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目

相似海外基金

Toward synthetic chemically defined mRNA for human therapeutics
用于人类治疗的合成化学定义的 mRNA
  • 批准号:
    10649299
  • 财政年份:
    2023
  • 资助金额:
    $ 7.09万
  • 项目类别:
Oxidative Stress and Mitochondrial Dysfunction in Chemogenetic Heart Failure
化学遗传性心力衰竭中的氧化应激和线粒体功能障碍
  • 批准号:
    10643012
  • 财政年份:
    2023
  • 资助金额:
    $ 7.09万
  • 项目类别:
Studies of Chemically Labile Alkylation Damage in DNA
DNA 中化学不稳定烷基化损伤的研究
  • 批准号:
    10735154
  • 财政年份:
    2023
  • 资助金额:
    $ 7.09万
  • 项目类别:
Characterization of the Regulation and Gene Targets of TBX2 in Rhabdomyosarcoma
横纹肌肉瘤中 TBX2 的调控和基因靶点的表征
  • 批准号:
    10731025
  • 财政年份:
    2023
  • 资助金额:
    $ 7.09万
  • 项目类别:
NAD(P)H quinone oxidoreductase 1 (NQO1)-mediated bypass of mitochondrial electron transport chain with artificial and endogenous substrates
NAD(P)H 醌氧化还原酶 1 (NQO1) 介导的人工和内源底物线粒体电子传递链旁路
  • 批准号:
    10789749
  • 财政年份:
    2023
  • 资助金额:
    $ 7.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了